Oftaquix (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that are required for DNA replication and transcription. Inhibiting these enzymes stops bacterial cells from multiplying, leading to a bactericidal effect against susceptible Gram‑positive and Gram‑negative bacteria.

The dosage of Oftaquix is determined by the prescribing clinician based on the type and severity of infection, patient age, renal function and other clinical factors. Physicians set the dose and duration according to approved guidelines and individual patient needs.

Levofloxacin is classified as a pregnancy‑category C drug. It should be used only when the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional, as the drug can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levofloxacin offers broad‑spectrum coverage against many Gram‑negative and Gram‑positive pathogens and has the convenience of once‑daily oral dosing. Compared with older fluoroquinolones, it provides higher potency against certain respiratory and urinary pathogens, though safety considerations such as tendon risk remain similar across the class.

Oftaquix tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Oftaquix is supplied as an oral tablet and is taken by mouth with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with an adequate amount of water.

Serious adverse reactions can include tendon rupture or inflammation, peripheral neuropathy, severe allergic reactions such as Stevens‑Johnson syndrome, QT‑interval prolongation and Clostridioides difficile‑associated colitis. Patients should be advised to seek immediate medical attention if they experience any of these symptoms.

Levofloxacin is contraindicated in patients with a known hypersensitivity to fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and individuals with certain cardiac conditions that predispose them to QT prolongation. Clinicians should evaluate each patient’s medical history before prescribing.